GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMA) » Definitions » Total Assets

XOMA (XOMA Royalty) Total Assets : $221.28 Mil (As of Dec. 2024)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Total Assets?

XOMA Royalty's Total Assets for the quarter that ended in Dec. 2024 was $221.28 Mil.

During the past 12 months, XOMA Royalty's average Total Assets Growth Rate was 43.60% per year. During the past 3 years, the average Total Assets Growth Rate was 17.00% per year. During the past 5 years, the average Total Assets Growth Rate was 24.30% per year. During the past 10 years, the average Total Assets Growth Rate was 43.10% per year.

During the past 13 years, XOMA Royalty's highest 3-Year average Total Assets Growth Rate was 203.80%. The lowest was -48.90%. And the median was -0.60%.

Total Assets is connected with ROA %. XOMA Royalty's annualized ROA % for the quarter that ended in Dec. 2024 was -7.14%. Total Assets is also linked to Revenue through Asset Turnover. XOMA Royalty's Asset Turnover for the quarter that ended in Dec. 2024 was 0.01.


XOMA Royalty Total Assets Historical Data

The historical data trend for XOMA Royalty's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Total Assets Chart

XOMA Royalty Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 125.29 166.56 140.38 234.30 221.28

XOMA Royalty Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.30 219.42 243.28 223.34 221.28

XOMA Royalty Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

XOMA Royalty's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=81.921+139.356
=221.28

XOMA Royalty's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=81.921+139.356
=221.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA Royalty  (NAS:XOMA) Total Assets Explanation

Total Assets is connected with ROA %.

XOMA Royalty's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-15.872/( (223.34+221.277)/ 2 )
=-15.872/222.3085
=-7.14 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

XOMA Royalty's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=2.342/( (223.34+221.277)/ 2 )
=2.342/222.3085
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

XOMA Royalty Total Assets Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Matthew D Perry director, other: See Explanation of Responses ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104